A Trial Looking at Treating Dry Mouth After Radiotherapy for Head and Neck Cancer

NCT ID: NCT02941276

Last Updated: 2021-11-03

Basic Information

• Recruitment Status: COMPLETED
• Clinical Phase: NA
• Total Enrollment: 84 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2011-11-30
• Study Completion Date: 2014-11-30

Brief Summary

This trial is looking at using an intra-oral electrostimulating device for the management of radiotherapy-induced dry mouth.

Detailed Description

Dry mouth is a common complaint of radiotherapy for cancer of the head and neck region. It is a distressing often persistent condition which can lead to longlasting oral discomfort, dental infections, diminished quality of life, social isolation and loneliness. Unfortunately, current therapies of dry mouth are often unsatisfactory, expensive and may result in adverse effects. A novel intraoral electronic device has recently been developed to treat dry mouth. The device, acting as a "salivary pacemaker", harmlessly stimulates nerves of the salivary glands and does not cause adverse side effects. The aim of this proposal is to assess the longterm effects of such a device in this population, which have yet to be investigated, to demonstrate whether its daily application is an effective method of lessening dry mouth and improving life quality. 84 individuals will be enrolled in the study to use the device for 12 months, after receiving appropriate instructions. 42 participants (out of 84) will act as controls as they will receive a sham device that will not deliver electric stimuli but only tactile stimulation (like using a chewing gum). All participants will be allowed to continue using their routine local therapy for dry mouth (e.g. artificial saliva) during the study. Each participant will keep a diary relevant to the frequency of use and potential changes in dry mouth sensation. Participants will also be asked to attend hospital appointments to measure changes in saliva production and complete questionnaires on their dry mouth and quality of life. The device has the potential to radically change current clinical practice. If the trial is successful, the use of the device will provide patients having radiation-induced dry mouth with a safe and drug-free therapeutic modality.

Conditions

Xerostomia; Head and Neck Neoplasms

Study Design

• Allocation Method: RANDOMIZED
• Intervention Model: PARALLEL
• Primary Study Purpose: TREATMENT
• Blinding Strategy: TRIPLE

Study Groups

Group A

Active electrostimulator device (intra-oral active second generation Saliwell GenNarino) (Saliwell Ltd., Harutzim, Israel)

Group Type: EXPERIMENTAL

Active Electrostimulator device

Intervention Type: DEVICE

Patients who will receive a fully functioning device

Group B

Sham electrostimulator device (intra-oral sham second generation Saliwell GenNarino) (Saliwell Ltd., Harutzim, Israel)

Group Type: SHAM_COMPARATOR

Sham Electrostimulator device

Intervention Type: DEVICE

Patients who will receive a device that does not release electric stimuli (but provided mechanical/tactile stimulation)

Interventions

Active Electrostimulator device

Patients who will receive a fully functioning device

Intervention Type: DEVICE

Sham Electrostimulator device

Patients who will receive a device that does not release electric stimuli (but provided mechanical/tactile stimulation)

Intervention Type: DEVICE

Eligibility Criteria

Inclusion Criteria

1. To be at least 18 years old

2. To have received more than 40 Gy of external beam RT for cancer in the H&N region at least 4 months before entry into the study

3. To have grade 1 or 2 of RTOG/EORTC Late Radiation Morbidity Scoring Schema

4. To have a degree of minimum degree of dryness of 50mm (≥50mm) on a 100mm VAS scale (0=no dryness; 100

=maximum dryness).

5. To have demonstrable residual salivary gland function (increase in salivary flow on appropriate stimulation (e.g. chewing paraffin wax)

6. To have at least one parotid gland

Exclusion Criteria

1. To have severe uncontrolled systemic disease (on the basis of the classification of the American Society of Anesthesiology: ASA IV and ASA V)

2. To have known allergy to materials similar to those used in the investigational product

3. To wear other active implants such as cardiac pacemaker or defibrillator, or hearing aids

4. To have an unstimulated whole salivary flow of 0ml/15min (complete absence of unstimulated salivary flow as measured via sialometry for 15 minutes).

5. To use of pilocarpine as systemic therapy

6. To have grade 3 RTOG/EROTC or no resting saliva (sialometry = 0mL/1.5 min)

7. To have no parotid glands

• Minimum Eligible Age: 18 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

University College, London

OTHER

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Principal Investigators

Dr Stefano Fedele, PhD

Role: PRINCIPAL_INVESTIGATOR

University College, London

Other Identifiers

11/0138

Identifier Type: -

Identifier Source: org_study_id